Assessment of Protective Properties of Optimized Flagellin Derivative Against Biologically Harmful Effects of Ionizing Irradiation During Space Flight, Phase I

The goal of this proposal is to explore a novel proprietary biopharmaceutical agent, named deltaFL-AA', a first in the series of innovative radioprotectors to act as an agent providing protection of the organism against major space radiation risks. These risks include organism death resulting from acute irradiation as well as radiation-induced carcinogenesis caused by low-dose exposure. An unprecedented radioprotective potency of deltaFL-AA' demonstrated by its ability to cure 100% of mice from supralethal (14 Gy) doses of gamma-irradiation and its strong immunostimulatory properties (especially the ability to trigger natural killer response, which is well established as one of the antitumor firewalls) make this drug an extremely attractive candidate for testing in a NASA-funded program.

This is a mature technology (TRL 7+) — the realistic path in is usually NASA's Technology Transfer Program: licensing an existing NASA patent, or a Space Act Agreement to use NASA facilities/expertise directly. NASA also runs a startup licensing program with no upfront fee for companies formed to commercialize a specific NASA technology.

None of these are guaranteed paths for this specific project — TechPort itself doesn't have an "apply" button. Reaching out to the contact(s) above with a specific question is usually the fastest way to find out what's actually open.